In a recently released analyst update to clients, GMP Securities‘ Healthcare Equity Research Analyst, Robert Fagan just reiterated his buy rating on shares of Trulieve Cannabis Corp. (CSE:TRUL) (OTC:TCNNF) with a sky-high price target.
Robert Fagan, CFA’s price target of $26 CAD per share, equivalent to roughly $19.69 USD per share, implies a potential upside of approximately 54.21% based on Trulieve’s last traded price of $16.86 CAD on the CSE.
According to Fagan’s recent update to clients:
“With TRUL’s five brand partnerships, the company has achieved the most diverse brand and product offering in FL, with its closest competitor having only two brand partnerships. This in turn should help TRUL support its market share as multiple brand offerings should provide a differentiator in a market where competitive pressures are expected to increase as more operators enter the market.”
Be sure to subscribe to updates here so you never miss an important development.
Get Real-Time Updates from MJobserver.com